Literature DB >> 16841525

[Socio-economic impact of migraine and headaches in France].

Jean-Paul Auray1.   

Abstract

The International Headache Society has defined a clear diagnostic guideline classifying headaches into three categories. It is now well known that headaches have a significant effect on the quality of life and the professional, school or family activities of individuals, and that the economic impact is far from negligible. An extensive survey drawn from a sample of 10 585 individuals in the French adult population was carried out in the last three months of 1999. The results showed a prevalence of 17.3% for migraine and nearly 30% for headaches. The average expenditure for a headache patient is about 220 Euro, divided as follows: 10% for GP consultations, 11% for laboratory evaluations, 17% for specialist consultations, 18% for drugs and 44% for hospital costs. But this breakdown depends largely on the headache category. Although the most acute headaches lead to the most severe deterioration of quality of life, professional or school activities are not affected in the same way.

Entities:  

Mesh:

Year:  2006        PMID: 16841525

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  12 in total

Review 1.  The impact of drug therapy on quality of life in headache and migraine.

Authors:  G D Solomon; D G Litaker
Journal:  Pharmacoeconomics       Date:  1997-04       Impact factor: 4.981

2.  Cost-effectiveness of sumatriptan in a managed care population.

Authors:  R F Legg; D A Sclar; N L Nemec; J Tarnai; J I Mackowiak
Journal:  Am J Manag Care       Date:  1997-01       Impact factor: 2.229

3.  Incremental absenteeism due to headaches in migraine: results from the Mig-Access French national cohort.

Authors:  P Michel; J F Dartigues; G Duru; J Moreau; R Salamon; P Henry
Journal:  Cephalalgia       Date:  1999-06       Impact factor: 6.292

4.  Medication use and disability among migraineurs: a national probability sample survey.

Authors:  D D Celentano; W F Stewart; R B Lipton; M L Reed
Journal:  Headache       Date:  1992-05       Impact factor: 5.887

5.  Impact of sumatriptan on clinic utilization and costs of care in migraineurs.

Authors:  D G Litaker; G D Solomon; J R Genzen
Journal:  Headache       Date:  1996-10       Impact factor: 5.887

6.  Loss of productivity and quality of life in migraine sufferers among French workers: results from the GAZEL cohort.

Authors:  P Michel; J F Dartigues; A Lindoulsi; P Henry
Journal:  Headache       Date:  1997-02       Impact factor: 5.887

7.  MIG ACCESS: a population-based, nationwide, comparative survey of access to care in migraine in France.

Authors:  P Michel; P Pariente; G Duru; J P Dreyfus; H Chabriat; P Henry; J P Dreyfuss
Journal:  Cephalalgia       Date:  1996-02       Impact factor: 6.292

8.  Prevalence and clinical characteristics of migraine in France.

Authors:  P Henry; J P Auray; A F Gaudin; J F Dartigues; G Duru; M Lantéri-Minet; C Lucas; A Pradalier; G Chazot; A El Hasnaoui
Journal:  Neurology       Date:  2002-07-23       Impact factor: 9.910

9.  [Quality of life and migraine. Validation of the QVM questionnaire in hospital consultation and in general medicine].

Authors:  A Richard; P Henry; G Chazot; H Massiou; S Tison; R Marconnet; A Chicoye; H d'Allens
Journal:  Therapie       Date:  1993 Mar-Apr       Impact factor: 2.070

10.  Healthcare resource use and costs associated with migraine in a managed healthcare setting.

Authors:  J C Clouse; J T Osterhaus
Journal:  Ann Pharmacother       Date:  1994-05       Impact factor: 3.154

View more
  2 in total

Review 1.  Impact of headache in Europe: a review for the Eurolight project.

Authors:  Lars Jacob Stovner; Colette Andrée
Journal:  J Headache Pain       Date:  2008-04-17       Impact factor: 7.277

Review 2.  Improving care through health economics analyses: cost of illness and headache.

Authors:  Francesco Saverio Mennini; Lara Gitto; Paolo Martelletti
Journal:  J Headache Pain       Date:  2008-07-05       Impact factor: 7.277

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.